Notable Mergers and Acquisitions of the Day 5/29: FTGX, CLDX/CRGN
More News related to CLDX
- Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009
- Merriman Curhan Positive On Celldex Therapeutics (CLDX) After Results and Ahead of Events
- Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results
- Celldex Therapeutics (CLDX) Announces Positive Results From Phase Studies of CDX-1307
- Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307
More News related to CRGN
- Celldex (CLDX) Closes Acquisition of CuraGen (CRGN)
- CuraGen's (CRGN) CR011-vcMMAE Phase I/II Trial Meets Efficacy Criteria
- Morning Movers 6/3: TIVO, APPA, CTIC, PMI, SAY, TSRA Higher; VLO, MIND, STLD, CRGN, AET Lower
- Levi & Korsinsky Investigating Breach of Fiduciary Duty by Board of CuraGen (CRGN)
- At ASCO, CuraGen (CRGN) Updates CR011-vcMMAE Data
More News related to FTGX
- RCN Corporation Withdraws Proposal To Buy FiberNet Telecom (FTGX) For $12.50 A Share
- Unusual 11 Mid-Day Movers 5/29: JCG, STSI, PNSN, INCY Higher; CPRX, OCLS, GM, WTSLA Lower
- Notable Mergers and Acquisitions of the Day 5/29: FTGX, CLDX/CRGN
- After-Hours Movers 5/28: JCG, ALTI, FTGX, ITI, OVTI Higher; ESL, JMBA, KRC, MRVL Lower
- FiberNet Telecom (FTGX) to be Acquired by Zayo Group for $11.45/Share in Cash
More News related to Special Reports
- Analyst Sees Google (GOOG) Headed Higher
- RBC Lifts Price Target on Best Buy (BBY) to $49
- Broadpoint.AmTech Lowers Est and Price Target on Research In Motion (RIMM), But Sticks With Buy Rating
- Deere (DE) Shares Rising as Analysts Getting Bullish
- Soleil Calls Fertilizer Stocks 'Over-Valued', Recommends Taking Profits (POT, MOS, IPI)
- FiberNet Telecom Group, Inc. (Nasdaq: FTGX) announced today that it has entered into a definitive Agreement and Plan of Merger with Zayo Group, LLC and Zayo Merger Sub, Inc. Each share of FiberNet Telecom Group, Inc. common stock issued and outstanding immediately prior to the effective time of the merger will be entitled to receive $11.45 in cash (subject to potential adjustment under the merger agreement)
The transaction is subject to the approval of FiberNet's stockholders at a special meeting, FCC and state regulatory approvals, and customary conditions. The transaction is not subject to any financing condition. The Board of Directors of FiberNet approved the agreement and recommended the adoption of the agreement by FiberNet's stockholders. The transaction is expected to be completed during the third quarter of 2009.
- Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced it has entered into a definitive agreement to acquire CuraGen Corporation (Nasdaq: CRGN). The acquisition will add a portfolio of oncology-focused, fully-owned antibodies to Celldex's Precision Targeted Immunotherapy Platform. Celldex will acquire CuraGen in a tax-free stock-for-stock transaction, which values CuraGen at approximately $94.5 million, subject to certain adjustments described within the definitive agreement. In addition to its pipeline, CuraGen is expected to have a cash balance of at least $54.5 million net of certain acquisition-related costs and CuraGen convertible debt at the transaction's close, which is anticipated to occur in the third quarter of 2009. Concurrent with the closing of the transaction, Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen, will join the Celldex Board of Directors.
Related Categories
Special ReportsStocks Mentioned
-0.04
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
